Browse > Article

Plasma B-type natriuretic peptide (BNP): a useful marker for anthracycline-induced cardiotoxicity in Korean children with cancer  

Lee, Hyun Dong (Department of Pediatrics, College of Medicine, Yeungnam University)
Lee, Jae Min (Department of Pediatrics, College of Medicine, Yeungnam University)
Lee, Yong Jik (Department of Pediatrics, College of Medicine, Yeungnam University)
Lee, Young Hwan (Department of Pediatrics, College of Medicine, Yeungnam University)
Hah, Jeong Ok (Department of Pediatrics, College of Medicine, Yeungnam University)
Publication Information
Clinical and Experimental Pediatrics / v.50, no.8, 2007 , pp. 774-780 More about this Journal
Abstract
Purpose : The anthracyclines (AC) are widely used chemotherapeutic agents for pediatric cancers. However, the therapeutic use of these agents is limited by their cardiotoxicity. The aim of the present study was to investigate the usefulness of plasma B-type natriuretic peptide (BNP) levels as a marker for AC-induced cardiotoxicity compared to echocardiography in Korean children with cancer. Methods : Fifty-five pediatric cancer patients who had received chemotherapy including AC were enrolled. The cumulative AC doses, clinical symptoms, and two echocardiography parameters, left ventricular fractional shortening (LVFS) and left ventricular ejection fraction (LVEF), were studied and compared with plasma BNP levels. Results : In 55 patients, plasma BNP levels were measured 115 times and echocardiographies were performed 64 times. The median cumulative dose of AC was $325mg/m^2$ (range 120-600; mean 345) and the median plasma BNP level was 10 pg/mL (range 5-950; mean 31). The cumulative AC doses correlated significantly with the plasma BNP levels (P=0.002). The plasma BNP levels correlated significantly with LVFS (P=0.018) and LVEF (P=0.025). Dilated cardiomyopathies were identified in three patients. LVFS and LVEF decreased and plasma BNP levels increased in a patient with acute dilated cardiomyopathy and in that with symptomatic chronic dilated cardiomyopathy. However, LVFS, LVEF and plasma BNP levels were normal in a patient with asymptomatic chronic dilated cardiomyopathy. Conclusion : The results of this study demonstrated that plasma BNP levels could be used as a marker for AC-induced cardiotoxicity; they showed good correlation with echocardiography findings in pediatric cancer patients. Plasma BNP levels may be used for the detection and management of AC-induced cardiotoxicity in Korean children with cancer.
Keywords
Anthracycline; Cardiotoxic; B-type natriuretic peptide;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Meinardi MT, Gietema JA, van Veldhuisen DJ, van der Graaf WT, Vries EG, Sleijfer DT. Long-term chemotherapyrelated cardiovascular morbidity. Cancer Treat Rev 2000;26: 429-47   DOI   ScienceOn
2 Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Circulation 1996; 93:1963-9   DOI   ScienceOn
3 McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 2003;4:72-80
4 Triage BNP Test Product Insert. San Diego CA: Biosite Diagnostics Inc. 2000
5 Doroshow JH, Locker GY, Myers CE. Enzymatic defenses of the mouse heart against reactive oxygen metabolites: alterations produced by doxorubicin. J Clin Invest 1980;65:128-35   DOI
6 Suzuki T, Hayashi D, Yamazaki T, Mizuno T, Kanda Y, Komuro I, et al. Elevated B-type natriuretic peptide levels after anthracycline administration. Am Heart J 1998;136:362-3   DOI   ScienceOn
7 Daugaard G, Lassen U, Bie P, Pedersen EB, Jensen KT, Abildgaard U, et al. Natriuretic peptides in the monitoring of anthracycline induced reduction in left ventricular ejection fraction. Eur J Heart Fail 2005;7:87-93   DOI   ScienceOn
8 Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1347-51
9 Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992;70:73-7   DOI   ScienceOn
10 Pinarli FG, Oguz A, Tunaoglu FS, Karadeniz C, Gokcora N, Elbeg S. Late cardiac evaluation of children with solid tumors after anthracycline chemotherapy. Pediatr Blood Cancer 2005;44:370-7   DOI   ScienceOn
11 Shan K, Lincoff M, Young JB. Anthracycline induced cardiotoxicity. Ann Intern Med 1996;125:47-58   DOI   ScienceOn
12 Grenier MA, Lipshultz SE. Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 1998;25 (Suppl 10):72-85
13 Elbl L, Vasova I, Navratil M, Vorlicek J, Malaskova L, Spinar J. Comparison of plasmatic levels of B-natriuretic peptide with echocardiographic indicators of left ventricle function after doxorubicin therapy. Vnitr Lek 2006;52:563-70
14 Massin MM, Dresse MF, Schimitz V, Hoyoux C, Chantraine JM, Lepage P. Acute arrhythmogenicity of first-dose chemotherapeutic agents in children. Med Pediatr Oncol 2002; 39:93-8   DOI   ScienceOn
15 Ganz WI, Sridhar KS, Ganz SS, Gonzalez R, Chakko S, Serafini A. Review of tests for monitoring doxorubicin-induced cardiomyopathy. Oncology 1996;53:461-70   DOI   ScienceOn
16 Doroshow JH. Doxorubicin-induced cardiototoxicity. N Engl J Med 1991;324:843-5   DOI   ScienceOn
17 Steinherz LJ, Graham T, Hurwitz R, Sondheimer HM, Schwartz RG, Shaffer EM, et al. Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Children Cancer Study Group. Pediatrics 1992;89:942-9
18 Kunii Y, Kamada M, Ohtsuki S, Araki T, Kataoka K, Kageyama M, et al. Plasma brain natriuretic peptide and the evaluation of volume overload in infants and children with congenital heart disease. Acta Med Okayama 2003;57:191-7
19 Koch A, Singer H. Normal values of B type natriuretic peptide in infants, children, and adolescents. Heart 2003;89:875-8   DOI
20 Vanderheyden M, Bartunek J, Goethals M. Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 2004;6:261-8   DOI   ScienceOn
21 Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Safety 2000;22:263-302   DOI   ScienceOn
22 Simbre VC, Duffy SA, Dadlani GH, Miller TL, Lipshultz SE. Cardiotoxicity of cancer chemotherapy: implications for children. Paediatr Drugs 2005;7:187-202   DOI   ScienceOn
23 Aggarwal S, Pettersen MD, Bhambhani K, Gurczynski J, Thomas R, L'ecuyer T. B-type natriuretic peptide as a marker for cardiac dysfunction in anthracycline-treated children. Pediatric Blood Cancer. Early View. Published Online: 2006 Dec
24 Hayakawa H, Komada Y, Hirayama M, Hori H, Ito M, Sakurai M. Plasma levels of natriuretic peptides in relation to doxorubicin-induced cardiotoxicity and cardiac function in children with cancer. Med Pediatr Oncol 2001;37:4-9   DOI   ScienceOn
25 von Hoff DD, Layard MW, Basa P, Davis HL Jr, von Hoff AL, Rozencweig M, et al. Risk factors for doxorubicin-in-duced congestive heart failure. Ann Intern Med 1979;91: 710-7   DOI   ScienceOn
26 Steinherz LJ, Steinherz PG, Tan C. Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 1995;24:352-61   DOI   ScienceOn
27 Davidson NC, Naas AA, Hanson JK, Kennedy NS, Coutie WJ, Struthers AD. Comparison of atrial natriuretic peptide, B-type natriuretic peptide and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am J Cardiol 1996;77:828-31   DOI   ScienceOn
28 Sparano JA, Brown DL, Wolff AC. Predicting cancer therapy- induced cardiotoxicity: the role of troponins and other markers. Drug Safety 2002;25:301-11   DOI   ScienceOn
29 Alderton PM, Gross J, Green MD. Comparative study of doxorubicin, mitoxantrone and epirubicin in combination with ICRF-187 (ADR-529) in a chronic cardiotoxicity animal model. Cancer Res 1992;52:194-201
30 Cirillo R, Sacco G, Venturella S, Brightwell J, Giachetti A, Manzini S. Comparison of doxorubicin- and MEN 10755-induced long-term progressive cardiotoxicity in the rat. J Cardiovasc Pharmacol 2000;35:100-8   DOI   ScienceOn
31 Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin-T in pediatric patients at risk for myocardial injury. Circulation 1997;96:2641-8   DOI   ScienceOn
32 Wilkins MR, Redondo J, Brown LA. The natriuretic-peptide family. Lancet 1997;349:1307-10   DOI   ScienceOn
33 Bernstein D. Heart failure. In: Behrman RE, Kliegman RM, Jenson HB, editors. Nelson textbook of pediatrics. 17th ed. Philadelphia: WB Saunders Co, 2004:1583-4
34 Villani F, Meazza R, Materazzo C. Non-invasive monitoring of cardiac hemodynamic parameters in doxorubicin-treated patients: comparison with echocardiography. Anticancer Res 2006;26:797-801